Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study.

Sara BayatKoray TascilarDaniela BohrGerhard Krönke David Simon Johannes KnitzaFabian HartmannGeorg SchettArnd Kleyer

Published in: RMD open (2022)

In routine practice, BARI is effective as monotherapy in case of MTX intolerance with overall high drug persistence rates. No new safety signals were observed.

Keyphrases

combination therapy
healthcare
primary care
rheumatoid arthritis
adverse drug
clinical practice
randomized controlled trial
emergency department
quality improvement
clinical trial